Want to see SIGY full AI Analyst Report?
Total Valuation
Sigyn Therapeutics has a market cap or net worth of $41.44K. The enterprise value is $2.79M.
Market Cap$41.44K
Enterprise Value$2.79M
Share Statistics
Sigyn Therapeutics has 1,605,377 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,605,377
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sigyn Therapeutics’s return on equity (ROE) is 0.52 and return on invested capital (ROIC) is 52.83%.
Return on Equity (ROE)0.52
Return on Assets (ROA)-31.29
Return on Invested Capital (ROIC)52.83%
Return on Capital Employed (ROCE)0.42
Revenue Per Employee0.00
Profits Per Employee-840.98K
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sigyn Therapeutics is ―. Sigyn Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio0.00
PB Ratio-0.43
Price to Fair Value-0.43
Price to FCF-3.23
Price to Operating Cash Flow-0.11
PEG Ratio0.05
Income Statement
In the last 12 months, Sigyn Therapeutics had revenue of 0.00 and earned -3.36M in profits. Earnings per share was -2.09.
Revenue0.00
Gross Profit-1.36K
Operating Income-1.79M
Pretax Income-3.36M
Net Income-3.36M
EBITDA-1.78M
Earnings Per Share (EPS)-2.09
Cash Flow
In the last 12 months, operating cash flow was -654.39K and capital expenditures -3.00, giving a free cash flow of -654.39K billion.
Operating Cash Flow-654.39K
Free Cash Flow-654.39K
Free Cash Flow per Share-0.41
Dividends & Yields
Sigyn Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.20
52-Week Price Change-98.75%
50-Day Moving Average0.03
200-Day Moving Average0.67
Relative Strength Index (RSI)57.67
Average Volume (3m)1.22K
Important Dates
Sigyn Therapeutics upcoming earnings date is Nov 14, 2023, Before Open (Confirmed).
Last Earnings DateAug 14, 2023
Next Earnings DateNov 14, 2023
Ex-Dividend Date―
Financial Position
Sigyn Therapeutics as a current ratio of 0.01, with Debt / Equity ratio of -43.72%
Current Ratio0.01
Quick Ratio0.01
Debt to Market Cap1.11
Net Debt to EBITDA-1.70
Interest Coverage Ratio-2.49
Taxes
In the past 12 months, Sigyn Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Sigyn Therapeutics EV to EBITDA ratio is -3.25, with an EV/FCF ratio of -6.80.
EV to Sales0.00
EV to EBITDA-3.25
EV to Free Cash Flow-6.80
EV to Operating Cash Flow-6.80
Balance Sheet
Sigyn Therapeutics has $265.00 in cash and marketable securities with $3.18M in debt, giving a net cash position of -$3.18M billion.
Cash & Marketable Securities$265.00
Total Debt$3.18M
Net Cash-$3.18M
Net Cash Per Share-$1.98
Tangible Book Value Per Share-$4.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Sigyn Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast12.05%